Cibus (CBUS) FCF Margin (2016 - 2025)

Cibus (CBUS) posted FCF Margin of 1275.88% for Q4 2025, up 33.93% sequentially from 1931.22% in Q3 2025, and down 11655.0% YoY from N/an in Q4 2024.

Cibus (CBUS) FCF Margin (2016 - 2025) Analysis & Trends

Cibus has reported FCF Margin for 10 years, with the latest figure at 1275.88% in Q4 2025.

Quarterly FCF Margin fell 11655.0% year-over-year to 1275.88% in Q4 2025, while the trailing twelve-month figure through Dec 2025 was 1406.38% (down 2554.0% YoY) and the FY2025 annual result came in at 1406.38%, down 2554.0% from the prior year.
FCF Margin grew to 1275.88% in Q4 2025 per CBUS's latest filing, from 1931.22% in the prior quarter.
Over five years, FCF Margin peaked at 4.81% in Q2 2021 and troughed at 21715.62% in Q1 2022.
A 5-year average of 4273.86% and a median of 1757.36% in 2023 frame the typical range for FCF Margin.
The sharpest annual moves came in 2022 and 2023: FCF Margin slumped 2149559 bps in 2022, then soared 1606086 bps in 2023.
Over 5 years, FCF Margin stood at 225.17% in 2021, then slumped by 3891 bps to 8985.71% in 2022, then surged by 82 bps to 1583.5% in 2023, then grew by 27 bps to 1159.32% in 2024, then dropped by 10 bps to 1275.88% in 2025.
According to Business Quant data, FCF Margin over the past three periods registered 1275.88%, 1931.22%, and 1470.95% for Q4 2025, Q3 2025, and Q2 2025 respectively.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	FCF Margin (Qtr)
1	Vertex Pharmaceuticals	137.11 Bn	129.26 Bn	2.84 Bn	30.39%
2	Regeneron Pharmaceuticals	84.98 Bn	76.99 Bn	3.93 Bn	13.35%
3	Argenx Se	64.52 Bn	59.33 Bn	1.37 Bn	-
4	Moderna	53.23 Bn	48.09 Bn	52.00 Mn	-388.28%
5	BeOne Medicines	41.23 Bn	36.14 Bn	1.53 Bn	25.68%
6	Alnylam Pharmaceuticals	30.65 Bn	27.34 Bn	992.69 Mn	22.62%
7	Insmed	27.15 Bn	25.99 Bn	358.27 Mn	-22.35%
8	Royalty Pharma	26.98 Bn	26.14 Bn	-	70.82%
9	BioNTech SE	26.78 Bn	8.39 Bn	668.28 Mn	41.07%
10	Cibus	131.25 Mn	110.82 Mn	-	-

Download Data